Made Scientific and Regenicin Partner to Advance Innovative Skin Therapy for FDA Approval

A Promising Partnership in Cell Therapy

Made Scientific, Inc., a leading contract development and manufacturing organization (CDMO) based in the United States, has officially partnered with Regenicin, Inc., a biotechnology firm dedicated to regenerative therapies. This collaboration aims to advance the development of NovaDerm, an autologous cultured skin substitute designed to treat severe burns and chronic wounds toward obtaining product approval from the U.S. Food and Drug Administration (FDA).

A Sign of Progress

On April 22, 2026, the companies announced their manufacturing relationship, pointing toward a shared vision of improving patient care through innovative therapies. NovaDerm is expected to provide a safer and more effective treatment option for patients suffering from severe skin damage.

Under the new agreement, Made Scientific will supply end-to-end manufacturing services from its state-of-the-art Good Manufacturing Practices (GMP) facility located in Princeton, New Jersey. This setup will ensure rigorous quality control and compliance as the program proceeds from technology transfer to clinical production and regulatory support for Regenicin’s Investigational New Drug (IND) submission.

Syed T. Husain, Chairman and CEO of Made Scientific, expressed pride in the partnership, emphasizing that the relationship highlights their robust manufacturing capabilities. 'We are excited to work with Regenicin on NovaDerm and to support the development of such a critical treatment for patients,' said Husain. The intricate design of patient-specific treatments such as NovaDerm necessitates high levels of consistency and traceability, attributes that Made Scientific is well-equipped to provide.

Expert Insight and Confidence

Dr. K. E. Castro, PhD, who serves as the Director of Clinical Studies at Regenicin, also commented on this collaboration. 'Manufacturing a patient-specific treatment like NovaDerm requires a level of consistency and traceability that few CDMOs can deliver. Made Scientific's proven expertise in autologous manufacturing gives us confidence as we move towards our IND submission and first-in-human clinical trial,' stated Dr. Castro.

This partnership is a beacon of hope for the field of regenerative medicine, especially for those on the precipice of innovative therapies. It signifies a meeting of minds striving not only for clinical success but also for providing tangible solutions to healthcare challenges.

Focus on Innovation and Advancement

Made Scientific has been investing heavily in creating a state-of-the-art infrastructure and technological advancements to advance cell therapies. Their mission is to continually push boundaries while delivering notable results and facilitating clinical trials that lead to revolutionary treatment options for patients.

Regenicin, on its part, has committed itself to refining and commercializing regenerative therapies. The move toward launching NovaDerm is not just about the immediate clinical applications; it's about setting a new standard for wound treatment that could redefine patient recovery processes.

Founded in 2010, Regenicin has a seasoned management team that boasts a strong track record in bringing innovative medical devices to market. Their flagship product, NovaDerm®, utilizes a patient’s cells to create living, regenerative skin, reducing the need for extensive tissue harvesting and significantly shortening hospital stays.

Looking Ahead: What This Means for Patients

The collaboration between Made Scientific and Regenicin therefore embodies the convergence of science, innovation, and patient care. As both companies work diligently toward advancing NovaDerm and navigating the regulatory landscape of the FDA, the medical community watches closely. Patients with severe burns and chronic wounds stand to benefit immensely from the successful outcome of this partnership, opening the door to hope where there was once despair.

In summary, the alliance between Made Scientific and Regenicin marks a significant milestone in the pursuit of advanced regenerative therapies. As they work together to launch NovaDerm, there is optimism in the air for both companies and the patients that they ultimately aim to serve.